April 2016 Blog Posts (13)

Pfizer's Palbociclib Shows Antiproliferative Activity in Early-stage Breast Cancer

The molecularly targeted therapeutic palbociclib (Ibrance®; Pfizer), also known as PD0332991 which is used to treat advanced breast cancer, was effective in slowing the multiplication of cancer cells in patients diagnosed with early-stage breast cancer who received no prior therapy, according to data from a phase II clinical trial,…

Continue

Added by Editorial Team on April 20, 2016 at 1:00pm — No Comments

Genetics May Influence Risk for Breast Cancer After Chest Radiotherapy to Treat Childhood Cancer

Among females who received radiotherapy to the chest as part of treatment for a childhood cancer, those who had either of two specific genetic variants were at significantly higher risk of developing breast cancer later in life, according to research presented during the Annual Meeting of the American Association for Cancer Research (AACR) Annual Meeting, April 16-20, 2016.

“It has been well established that female survivors of…

Continue

Added by Editorial Team on April 20, 2016 at 9:00am — No Comments

Study Confirms Delays in Radiation Therapy Increase Chance of Breast Tumor Development in Women Treated for DCIS

Women who underwent treatment for ductal carcinoma in situ (DCIS), a noninvasive breast abnormality, were at higher risk of developing malignant breast tumors if they did not receive timely radiation therapy as part of their treatment, according to a study, funded by the Foundation for Barnes-Jewish Hospital and the Breast Cancer Research Foundation, presented in New Orleans during the annual meeting of the American…

Continue

Added by Editorial Team on April 20, 2016 at 12:30am — No Comments

Study Shows that Adding Multiple Biological Markers of Risk May Improve Breast Cancer Risk Prediction Models

Adding biological markers of risk to breast cancer risk prediction models currently in use in the clinic appears to improve risk prediction, especially for postmenopausal women not using hormone therapy (HT), according to research presented  during the Annual Meeting of the American Association for Cancer Research being held April 16-20, 2016 in New Orleans. [1]

Improved ability to identify a woman’s breast cancer risk could help more precisely tailor the use of…

Continue

Added by Editorial Team on April 19, 2016 at 9:30am — No Comments

Study Shows Physical Activity May Improve Prostate Cancer Prognosis

Prostate cancer patients and survivors who maintain a moderate to high level of physical activity may improve their survival prognosis, according to research presented at the Annual Meeting of the American Association for Cancer Research held in New Orleans, April 16-20, 2016

“Our results support evidence that prostate cancer survivors should adhere to physical activity…

Continue

Added by Editorial Team on April 18, 2016 at 10:00pm — No Comments

Presurgery Combination Therapy with Trastuzumab Emtansine and Pertuzumab Improves Outcomes for Women With HER2-positive Breast Cancer

Results from the I-SPY 2 TRIAL show that a neoadjuvant therapy combination of the antibody-drug conjugate trastuzumab emtansine, also known as T-DM1 (Kadcyla; Genentech/Roche) and…

Continue

Added by Editorial Team on April 18, 2016 at 9:30pm — No Comments

LOXO-101 Shows Continued Promise in Patients Whose Tumors Had NTRK Gene Fusions

The investigational drug LOXO-101, being developed by Loxo oncology and selectively targets a family of proteins called neurotrophic tyrosine kinase receptors or NTRKs, produced significant tumor regression in patients whose tumors had the NTRK gene fusions, according to data from a phase I clinical trial presented during the annual meeting of the American…

Continue

Added by Editorial Team on April 18, 2016 at 4:30pm — No Comments

Agendia's MammaPrint Reduces Post-surgery Chemotherapy in Early-stage Breast Cancer Patients

Among patients with early-stage breast cancer who were considered at high risk for disease recurrence based on clinical and biological criteria, the MammaPrint genetic test identified a large group of patients for whom five-year distant metastasis–free survival was equally good whether or not they received adjuvant chemotherapy (chemotherapy given post- surgery), according to results from…

Continue

Added by Editorial Team on April 18, 2016 at 8:30am — No Comments

In Preclinical Studies Sunscreens Delays Melanoma Incidence

The application of sunscreen with a protection factor of 30 (SPF30) prior to exposure to ultraviolet-B (UVB) light delayed melanoma onset in a mouse model of the disease, according to research presented during the annual meeting of the American Association for Cancer Research being held April 16-20, 2016. These data suggest that the mouse model can be used to identify new, more effective melanoma-preventing agents.

“Over the past 40 years, the melanoma incidence rate has consistently…

Continue

Added by Editorial Team on April 17, 2016 at 9:00pm — No Comments

Survival Rates of Metastatic Melanoma Patients Treated with anti-PD-1 immunotherapeutic Nivolumab Higher than Historical Rates

More than a third of metastatic melanoma patients (34%) who received the anti-PD-1 immunotherapeutic nivolumab (Opdivo®) in a phase I clinical trial, funded by Bristol-Myers Squibb, are still alive five years after starting treatment, according to research presented in News Orleans during the annual meeting of the…

Continue

Added by Editorial Team on April 17, 2016 at 8:30pm — No Comments

Entrectinib Shows Early Promise Against a Range of Cancer Types

The investigational anticancer therapeutic entrectinib, being developed by Ignyta, designed to targets the proteins TrkA/B/C, ROS1, and ALK, is safe, tolerable, and showed signs of clinical activity in patients who had several different types of cancer with NTRK1/2/3, ROS1, or ALK gene alterations and had not previously been treated with a Trk-, ROS1-, or ALK-directed targeted therapeutic.  This conclusion is based on results from two phase I clinical trials (the ALKA-372-001 study and the…

Continue

Added by Editorial Team on April 17, 2016 at 5:30pm — No Comments

New Targeted Therapeutic Shows Early Promise Against Tumors With BRAF and RAS Mutations

A new investigational anti-cancer therapeutic called BGB-283, which targets the RAF family of proteins, is safe, tolerable, and showed signs of clinical activity in patients who had a range of types of cancer with mutations in BRAF, KRAS, and NRAS. These conclusions are based on results from a phase I clinical trial, funded by BeiGene, presented earlier this year during the annual meeting if the…

Continue

Added by Editorial Team on April 17, 2016 at 4:30pm — No Comments

Study Shows CD4 T-cell Immunotherapy Targeting MAGE-A3 Shows Early Clinical Responses in Patients with Metastatic Cancer

An immunotherapy developed by genetically engineering CD4 T cells targeting a protein, MAGE-A3, in cancer cells was found to be safe in patients with metastatic cancers, with some having clinical responses, according to data from a phase I clinical trial, funded by Intramural Research Program of the National Institutes of Health (NIH), in Bethesda, Maryland, presented during the annual meeting of the American Association of Cancer…

Continue

Added by Editorial Team on April 17, 2016 at 2:00pm — No Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+